PTEN and PI3K/AKT in non-small-cell lung cancer

Pharmacogenomics

Volumn 16, Issue 16, 2015, Pages 1843-1862

  Pérez Ramírez, Cristina ^a,b   Canãdas Garre, Marisa ^a   Molina, Miguel Ángel ^c   Faus Dáder, Mariá José ^b   Calleja Hernández, Miguel Ángel ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

EGFR; NSCLC; pharmacogenetics; PI3K; PTEN; resistance; TKI

Indexed keywords

AFATINIB; BORTEZOMIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; IDELALISIB; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RIDAFOROLIMUS; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; PTEN PROTEIN, HUMAN;

CANCER MORTALITY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CAUSE OF DEATH; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME INACTIVATION; GENE MUTATION; HUMAN; LUNG CANCER; NON SMALL CELL LUNG CANCER; NONHUMAN; REVIEW; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; GENETIC EPIGENESIS; GENETICS; LUNG NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; EPIGENESIS, GENETIC; HUMANS; LUNG NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE;

EID: 84947915756     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.122     Document Type: Review

References (208)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 65(1), 5-29 (2015).
2. AJCC Cancer Staging Manual (7th Edition). Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds). Springer, NY, USA, 649 (2010).
3. Herbst RS HJ, Lippman SM. Lung cancer. N. Engl. J. Med. 359(13), 1367-1380 (2008).
4. Molina JR, Yang P, Cassivi SD et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83(5), 584-594 (2008).
5. Kelly K, Crowley J, Bunn PA Jr Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced nonsmall-cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 19(13), 3210-3218 (2001).
6. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 20(21), 4285-4291 (2002).
7. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346(2), 92-98 (2002).
8. Fossella F, Pereira JR, Von Pawel J et al. Randomized, multinational, Phase I+II study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 21(16), 3016-3024 (2003).
9. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361(10), 958-967 (2009).
10. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
11. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
12. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (NY, USA) 304(5676), 1497-1500 (2004).
13. Kosaka T, Yatabe Y, Endoh H et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64(24), 8919-8923 (2004).
14. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97(5), 339-346 (2005).
15. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101(36), 13306-13311 (2004).
16. Yang JC, Hirsh V, Schuler M et al. Symptom control and quality of life in LUX-Lung 3: a Phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31(27), 3342-3350 (2013).
17. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58(1), 95-103 (2007).
18. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12(2), 175-180 (2011).
19. Inoue A, Kobayashi K, Maemondo M et al. Updated overall survival results from a randomized Phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive nonsmall cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann. Oncol. 24(1), 54-59 (2013).
20. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol. 11(2), 121-128 (2010).
21. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12(8), 735-742 (2011).
22. Jackman D, Pao W, Riely GJ et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 28(2), 357-360 (2010).
23. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13(3), 239-246 (2012).
24. Kobayashi S BT, Dayaram T, Jänne Pa et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352(8), 786-792 (2005).
25. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2(3), e73 (2005).
26. Tomizawa K, Suda K, Onozato R et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer 74(1), 139-144 (2011).
27. Thomson S, Buck E, Petti F et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 65(20), 9455-9462 (2005).
28. Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51(2), 181-191 (2006).
29. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2(1), e17 (2005).
30. Massarelli E, Varella-Garcia M, Tang X et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. 13(10), 2890-2896 (2007).
31. Lim WT, Zhang WH, Miller CR et al. PTEN and phosphorylated AKT expression and prognosis in early-and late-stage non-small cell lung cancer. Oncol. Reports 17(4), 853-857 (2007).
32. Arcila ME, Chaft JE, Nafa K et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin. Cancer Res. 18(18), 4910-4918 (2012).
33. Ohashi K, Sequist LV, Arcila ME et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl Acad. Sci. USA 109(31), E2127-E2133 (2012).
34. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalling. Science (NY, USA) 316(5827), 1039-1043 (2007).
35. Yano S, Wang W, Li Q et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68(22), 9479-9487 (2008).
36. Byers LA, Diao L, Wang J et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19(1), 279-290 (2013).
37. Wu F, Li J, Jang C, Wang J, Xiong J. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of nonsmall cell lung carcinoma. Int. J. Clin. Exp. Pathol. 7(10), 6653-6661 (2014).
38. Zhang Z, Lee JC, Lin L et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genet. 44(8), 852-860 (2012).
39. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273(22), 13375-13378 (1998).
40. Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signalling. Biochim. Biophys. Acta 1470(1), M21-M35 (2000).
41. Bepler G, Sharma S, Cantor A et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J. Clin. Oncol. 22(10), 1878-1885 (2004).
42. Sui L, Dong Y, Watanabe Y et al. Alteration and clinical relevance of PTEN expression and its correlation with survivin expression in epithelial ovarian tumors. Oncol.Rep. 15(4), 773-778 (2006).
43. Kokubo Y, Gemma A, Noro R et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br. J. Cancer 92(9), 1711-1719 (2005).
44. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signalling. Clin. Cancer Res. 9(12), 4340-4346 (2003).
45. Yan X, Fraser M, Qiu Q, Tsang BK. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol. Oncol. 102(2), 348-355 (2006).
46. Yanagawa N, Leduc C, Kohler D et al. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. J. Thorac Oncol. 7(10), 1513-1521 (2012).
47. Sharrard RM, Maitland NJ. Alternative splicing of the human PTEN/MMAC1/TEP1 gene. Biochim. Biophys. Acta 1494(3), 282-285 (2000).
48. Steck PA, Pershouse MA, Jasser SA et al. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet. 15(4), 356-362 (1997).
49. Lee JO, Yang H, Georgescu MM et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99(3), 323-334 (1999).
50. Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J. Biol Chem. 274(13), 8347-8350 (1999).
51. Sansal I,Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 22(14), 2954-2963 (2004).
52. Auger KR, Serunian LA, Soltoff SP et al. PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell 57(1), 167-175 (1989).
53. Coughlin SR, Escobedo JA, Williams LT. Role of phosphatidylinositol kinase in PDGF receptor signal transduction. Science (NY, USA) 243(4895), 1191-1194 (1989).
54. Whitman M, Kaplan DR, Schaffhausen B et al. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 315(6016), 239-242 (1985).
55. Scrima M, De Marco C, Fabiani F et al. Signalling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydilinositol-3 kinase. PLoS ONE 7(2), e30427 (2012).
56. Jin G, Kim MJ, Jeon HS et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 69(3), 279-283 (2010).
57. Marsit CJ, Zheng S, Aldape K et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Human Pathol. 36(7), 768-776 (2005).
58. Soria JC, Lee HY, Lee JI et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin. Cancer Res. 8(5), 1178-1184 (2002).
59. Spoerke JM, O'brien C, Huw L et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin. Cancer Res. 18(24), 6771-6783 (2012).
60. Sos ML, Koker M, Weir BA et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 69(8), 3256-3261 (2009).
61. Yamamoto C, Basaki Y, Kawahara A et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res. 70(21), 8715-8725 (2010).
62. Wu Z, Gioeli D, Conaway M, Weber MJ, Theodorescu D. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate 68(9), 935-944 (2008).
63. Endoh H, Yatabe Y, Kosaka T et al. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J. Thorac. Oncol. 1(7), 629-634 (2006).
64. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl. Cancer Inst. 91(22), 1922-1932 (1999).
65. Bruni P, Boccia A, Baldassarre G et al. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 19(28), 3146-3155 (2000).
66. Healy E, Rehman I, Angus B, Rees JL. Loss of heterozygosity in sporadic primary cutaneous melanoma. Genes Chromosomes Cancer 12(2), 152-156 (1995).
67. Obata K, Morland SJ, Watson RH et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 58(10), 2095-2097 (1998).
68. Perren A, Weng LP, Boag AH et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. 155(4), 1253-1260 (1999).
69. Teng DH, Hu R, Lin H et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 57(23), 5221-5225 (1997).
70. Wang SI, Puc J, Li J et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 57(19), 4183-4186 (1997).
71. Yokomizo A, Tindall DJ, Hartmann L et al. Mutation analysis of the putative tumor suppressor PTEN/MMAC1 in human ovarian cancer. Int. J. Oncol. 13(1), 101-105 (1998).
72. Forgacs E, Biesterveld EJ, Sekido Y et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 17(12), 1557-1565 (1998).
73. Kohno T, Takahashi M, Manda R, Yokota J. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer 22(2), 152-156 (1998).
74. Kawanishi M, Kohno T, Otsuka T et al. Allelotype and replication error phenotype of small cell lung carcinoma. Carcinogenesis 18(11), 2057-2062 (1997).
75. Shiseki M, Kohno T, Adachi J et al. Comparative allelotype of early and advanced stage non-small cell lung carcinomas. Genes Chromosomes Cancer 17(2), 71-77 (1996).
76. Petersen S, Wolf G, Bockmuhl U et al. Allelic loss on chromosome 10q in human lung cancer: association with tumour progression and metastatic phenotype. Br. J. Cancer 77(2), 270-276 (1998).
77. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68(4), 820-823 (1971).
78. Stjernstrom A, Karlsson C, Fernandez OJ et al. Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung. Cancer Med. 3(2), 337-348 (2014).
79. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41), 5497-5510 (2008).
80. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle (TX, USA) 3(10), 1221-1224 (2004).
81. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science (NY, USA) 304(5670), 554 (2004).
82. Shayesteh L, Lu Y, Kuo WL et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21(1), 99-102 (1999).
83. Rekhtman N, Paik PK, Arcila ME et al. Clarifying the spectrum of driver oncogene mutations in biomarkerverified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin. Cancer Res. 18(4), 1167-1176 (2012).
84. Wang L, Hu H, Pan Y et al. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS ONE 9(2), e88291 (2014).
85. Janku F, Lee JJ, Tsimberidou AM et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS ONE 6(7), e22769 (2011).
86. Kawano O, Sasaki H, Endo K et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 54(2), 209-215 (2006).
87. Kawano O, Sasaki H, Okuda K et al. PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer 58(1), 159-160 (2007).
88. Okudela K, Suzuki M, Kageyama S et al. PIK3CA mutation and amplification in human lung cancer. Pathol. Int. 57(10), 664-671 (2007).
89. Yamamoto H, Shigematsu H, Nomura M et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 68(17), 6913-6921 (2008).
90. Ji M GH, Gao C, Shi B, Hou P. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer 11, 147 (2011).
91. Jaiswal BS, Janakiraman V, Kljavin NM et al. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell 16(6), 463-474 (2009).
92. Noro R GA, Miyanaga a, Kosaihira S et al. PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Int. J. Oncol. 31(5), 1157-1163 (2007).
93. Yokomizo A, Tindall DJ, Drabkin H et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 17(4), 475-479 (1998).
94. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J. Med. Genet. 37(11), 828-830 (2000).
95. Liaw D, Marsh DJ, Li J et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genet. 16(1), 64-67 (1997).
96. Lynch ED, Ostermeyer EA, Lee MK et al. Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am. J. Hum. Genet. 61(6), 1254-1260 (1997).
97. Nelen MR, Van Staveren WC, Peeters EA et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum. Mol. Genet. 6(8), 1383-1387 (1997).
98. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (NY, USA) 275(5308), 1943-1947 (1997).
99. Meng F, Henson R, Wehbe-Janek H et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133(2), 647-658 (2007).
100. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cell. Biol. 20(14), 5010-5018 (2000).
101. Miller SJ, Lou DY, Seldin DC et al. Direct identification of PTEN phosphorylation sites. FEBS Lett. 528(1-3), 145-153 (2002).
102. Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 276(2), 993-998 (2001).
103. Vazquez F, Grossman SR, Takahashi Y et al. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J. Biol. Chem. 276(52), 48627-48630 (2001).
104. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110beta,-gamma, and-delta isoforms of class I phosphoinositide 3-kinase. Proc. Natl Acad. Sci. USA 103(5), 1289-1294 (2006).
105. Skolnik EY, Margolis B, Mohammadi M et al. Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell 65(1), 83-90 (1991).
106. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 27(41), 5486-5496 (2008).
107. Foukas LC, Berenjeno IM, Gray A et al. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc. Natl Acad. Sci. USA 107(25), 11381-11386 (2010).
108. Luk SK, Piekorz RP, Nurnberg B, Tony To SS. The catalytic phosphoinositol 3-kinase isoform p110delta is required for glioma cell migration and invasion. Eur. J. Cancer 48(1), 149-157 (2012).
109. Utermark T, Rao T, Cheng H et al. The p110alpha and p110beta isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev. 26(14), 1573-1586 (2012).
110. Carpenter CL, Duckworth BC, Auger KR et al. Purification and characterization of phosphoinositide 3-kinase from rat liver. J. Biol. Chem. 265(32), 19704-19711 (1990).
111. Engelman JA. Targeting PI3K signalling in cancer: opportunities. challenges and limitations. Nat. Rev. Cancer 9(8), 550-562 (2009).
112. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genetics 7(8), 606-619 (2006).
113. Katso R, Okkenhaug K, Ahmadi K et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Ann. Rev. Cell Dev. Biol. 17, 615-675 (2001).
114. Ali K, Camps M, Pearce WP et al. Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. J. Immunol. 180(4), 2538-2544 (2008).
115. Durand CA, Hartvigsen K, Fogelstrand L et al. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J. Immunol. 183(9), 5673-5684 (2009).
116. Guo H, Samarakoon A, Vanhaesebroeck B, Malarkannan S. The p110 delta of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation. J. Exp. Med. 205(10), 2419-2435 (2008).
117. Carpenter CL, Auger KR, Chanudhuri M et al. Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J. Biol. Chem. 268(13), 9478-9483 (1993).
118. Hiles ID, Otsu M, Volinia S et al. Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell 70(3), 419-429 (1992).
119. Shaw RJ, Cantley LC. Ras PI(3)K and mTOR signalling controls tumour cell growth. Nature 441(7092), 424-430 (2006).
120. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 13(22), 2905-2927 (1999).
121. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc. Natl Acad. Sci. USA 98(20), 10983-10985 (2001).
122. Jacinto E, Facchinetti V, Liu D et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127(1), 125-137 (2006).
123. Sarbassov DD, Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22(2), 159-168 (2006).
124. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictormTOR complex. Science 307(5712), 1098-1101 (2005).
125. Alessi DR, James SR, Downes CP et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Curr. Biol. 7(4), 261-269 (1997).
126. Currie RA, Walker KS, Gray A et al. Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem. J. 337 (Pt 3), 575-583 (1999).
127. Gao T, Brognard J, Newton AC. The phosphatase PHLPP controls the cellular levels of protein kinase C. J. Biol. Chem. 283(10), 6300-6311 (2008).
128. Brunet A, Bonni A, Zigmond MJ et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96(6), 857-868 (1999).
129. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NFkappaB by the Akt/PKB kinase. Curr. Biol. 9(11), 601-604 (1999).
130. Song G, Ouyang G, Bao S. The activation of Akt/PKB signalling pathway and cell survival. J. Cell. Mol. Med. 9(1), 59-71 (2005).
131. Zhou BP, Liao Y, Xia W et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3(11), 973-982 (2001).
132. Cantley LC. The phosphoinositide 3-kinase pathway. Science (NY, USA) 296(5573), 1655-1657 (2002).
133. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem. J. 415(3), 333-344 (2008).
134. Ozes ON, Mayo LD, Gustin JA et al. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401(6748), 82-85 (1999).
135. Jacinto E, Loewith R, Schmidt A et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6(11), 1122-1128 (2004).
136. Thoreen CC, Chantranupong L, Keys HR et al. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485(7396), 109-113 (2012).
137. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 412(2), 179-190 (2008).
138. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol. Med. 11(8), 353-361 (2005).
139. Martin DE, Hall MN. The expanding TOR signalling network. Curr. Opin. Cell Biol. 17(2), 158-166 (2005).
140. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27(41), 5527-5541 (2008).
141. Harrington LS, Findlay GM, Gray A et al. The TSC1-2 tumor suppressor controls insulin-PI3K signalling via regulation of IRS proteins. J. Cell Biol. 166(2), 213-223 (2004).
142. O'reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signalling and activates Akt. Cancer Res. 66(3), 1500-1508 (2006).
143. Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr. Opin. Cell Biol. 22(2), 169-176 (2010).
144. Volinia S, Hiles I, Ormondroyd E et al. Molecular cloning, cDNA sequence, and chromosomal localization of the human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene. Genomics 24(3), 472-477 (1994).
145. Huang CH, Mandelker D, Schmidt-Kittler O et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318(5857), 1744-1748 (2007).
146. Miled N, Yan Y, Hon WC et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317(5835), 239-242 (2007).
147. Ikenoue T, Kanai F, Hikiba Y et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65(11), 4562-4567 (2005).
148. Cannizzaro LA, Skolnik EY, Margolis B et al. The human gene encoding phosphatidylinositol-3 kinase associated p85 alpha is at chromosome region 5q12-13. Cancer Res. 51(14), 3818-3820 (1991).
149. Urick ME, Rudd ML, Godwin AK et al. PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res. 71(12), 4061-4067 (2011).
150. Philp AJ, Campbell IG, Leet C et al. The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61(20), 7426-7429 (2001).
151. Shekar SC, Wu H, Fu Z et al. Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J. Biol. Chem. 280(30), 27850-27855 (2005).
152. Bleeker FE, Felicioni L, Buttitta F et al. AKT1(E17K) in human solid tumours. Oncogene 27(42), 5648-5650 (2008).
153. Do H, Solomon B, Mitchell PL et al. Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res. Notes 1, 14 (2008).
154. Malanga D, Scrima M, De Marco C et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle (TX, USA) 7(5), 665-669 (2008).
155. Potter CJ, Huang H, Xu T. Drosophila TSC1 functions with TSC2 to antagonize insulin signalling in regulating cell growth, cell proliferation, and organ size. Cell 105(3), 357-368 (2001).
156. Young JM, Burley MW, Jeremiah SJ et al. A mutation screen of the TSC1 gene reveals 26 protein truncating mutations and 1 splice site mutation in a panel of 79 tuberous sclerosis patients. Ann. Hum. Genet. 62(Pt 3), 203-213 (1998).
157. Liang MC, Ma J, Chen L et al. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene 29(11), 1588-1597 (2010).
158. Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216), 1069-1075 (2008).
159. Takamochi K, Ogura T, Suzuki K et al. Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung. Am. J. Pathol. 159(5), 1941-1948 (2001).
160. Pirazzoli V, Nebhan C, Song X et al. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Reports 7(4), 999-1008 (2014).
161. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. PTEN is essential for embryonic development and tumour suppression. Nat. Genet. 19(4), 348-355 (1998).
162. Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl Acad. Sci. USA 95(26), 15406-15411 (1998).
163. Stambolic V, Suzuki A, De La Pompa JL et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95(1), 29-39 (1998).
164. Ramaswamy S, Nakamura N, Sansal I et al. A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2(1), 81-91 (2002).
165. Hughes K, Nikolakaki E, Plyte SE et al. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J. 12(2), 803-808 (1993).
166. Taelman VF, Dobrowolski R, Plouhinec JL et al. Wnt signalling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. Cell 143(7), 1136-1148 (2010).
167. Liu X, Rubin JS, Kimmel AR. Rapid Wnt-induced changes in GSK3beta associations that regulate betacatenin stabilization are mediated by G alpha proteins. Curr. Biol. 15(22), 1989-1997 (2005).
168. Rubinfeld B, Albert I, Porfiri E et al. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science (NY, USA) 272(5264), 1023-1026 (1996).
169. Trimboli AJ, Cantemir-Stone CZ, Li F et al. PTEN in stromal fibroblasts suppresses mammary epithelial tumours. Nature 461(7267), 1084-1091 (2009).
170. Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis. Model. Mech. 4(2), 165-178 (2011).
171. Bronisz A, Godlewski J, Wallace JA et al. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat. Cell Biol. 14(2), 159-167 (2012).
172. Wallace JA, Li F, Balakrishnan S et al. Ets2 in tumor fibroblasts promotes angiogenesis in breast cancer. PLoS ONE 8(8), e71533 (2013).
173. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 6(5), 392-401 (2006).
174. Weng LP, Brown JL, Baker KM et al. PTEN blocks insulinmediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway. Hum. Mol. Genet. 11(15), 1687-1696 (2002).
175. Liliental J, Moon SY, Lesche R et al. Genetic deletion of the PTEN tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr. Biol. 10(7), 401-404 (2000).
176. Cheng GZ, Park S, Shu S et al. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr. Cancer Drug Targets 8(1), 2-6 (2008).
177. Onoue T, Uchida D, Begum NM et al. Epithelialmesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. Int. J. Oncol. 29(5), 1133-1138 (2006).
178. Raftopoulou M, Etienne-Manneville S, Self A et al. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science (NY, USA) 303(5661), 1179-1181 (2004).
179. Tamura M, Gu J, Matsumoto K et al. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science (NY, USA) 280(5369), 1614-1617 (1998).
180. Kotelevets L, Van Hengel J, Bruyneel E et al. The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness. J. Cell Biol. 155(7), 1129-1135 (2001).
181. Emerling BM, Weinberg F, Liu JL et al. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proc. Natl Acad. Sci. USA 105(7), 2622-2627 (2008).
182. Quintero M, Brennan PA, Thomas GJ, Moncada S. Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1 alpha in cancer: role of free radical formation. Cancer Res. 66(2), 770-774 (2006).
183. Wang FS, Kuo YR, Wang CJ et al. Nitric oxide mediates ultrasound-induced hypoxia-inducible factor-1 alpha activation and vascular endothelial growth factor-A expression in human osteoblasts. Bone 35(1), 114-123 (2004).
184. Kim HS, Skurk C, Thomas SR et al. Regulation of angiogenesis by glycogen synthase kinase-3 beta. J. Biol. Chem. 277(44), 41888-41896 (2002).
185. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev. 14(16), 1983-1991 (2000).
186. Zundel W, Schindler C, Haas-Kogan D et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14(4), 391-396 (2000).
187. Eguez L, Lee A, Chavez JA et al. Full intracellular retention of GLUT4 requires AS160 Rab GTPase activating protein. Cell Metab. 2(4), 263-272 (2005).
188. Li X, Monks B, Ge Q, Birnbaum MJ. Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1 alpha transcription coactivator. Nature 447(7147), 1012-1016 (2007).
189. Sundqvist A, Bengoechea-Alonso MT, Ye X et al. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab. 1(6), 379-391 (2005).
190. Horie Y, Suzuki A, Kataoka E et al. Hepatocyte-specific PTEN deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Investig. 113(12), 1774-1783 (2004).
191. Fang M, Shen Z, Huang S et al. The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell 143(5), 711-724 (2010).
192. Shen WH, Balajee AS, Wang J et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128(1), 157-170 (2007).
193. Puc J, Keniry M, Li HS et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7(2), 193-204 (2005).
194. Mendes-Pereira AM, Martin SA, Brough R et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1(6-7), 315-322 (2009).
195. Song MS, Carracedo A, Salmena L et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell 144(2), 187-199 (2011).
196. Yilmaz OH, Valdez R, Theisen BK et al. PTEN dependence distinguishes hematopoietic stem cells from leukemia-initiating cells. Nature 441(7092), 475-482 (2006).
197. Zhang J, Grindley JC, Yin T et al. PTEN maintains hematopoietic stem cells and acts in lineage choice and leukemia prevention. Nature 441(7092), 518-522 (2006).
198. Chen Z, Trotman LC, Shaffer D et al. Crucial role of p53-dependent cellular senescence in suppression of PTENdeficient tumorigenesis. Nature 436(7051), 725-730 (2005).
199. Freeman DJ, Li AG, Wei G et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and-independent mechanisms. Cancer Cell 3(2), 117-130 (2003).
200. Kim JS, Lee C, Bonifant CL et al. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol. Cell. Biol. 27(2), 662-677 (2007).
201. Li AG, Piluso LG, Cai X et al. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol. Cell 23(4), 575-587 (2006).
202. Zhou M, Gu L, Findley HW et al. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res. 63(19), 6357-6362 (2003).
203. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Ann. Rev. Pathol. 4, 127-150 (2009).
204. Fumarola C, Bonelli MA, Petronini PG, Alfieri RR. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem. Pharmacol. 90(3), 197-207 (2014).
205. Heavey S, O'byrne KJ, Gately K. Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat. Rev. 40(3), 445-456 (2014).
206. Price KA, Azzoli CG, Krug LM et al. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J. Thorac. Oncol. 5(10), 1623-1629 (2010).
207. Soria JC, Shepherd FA, Douillard JY et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann. Oncol. 20(10), 1674-1681 (2009).
208. Reungwetwattana T, Molina JR, Mandrekar SJ et al. Brief report: a Phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. J. Thorac. Oncol. 7(5), 919-922 (2012).